📊 Evidence-Based Reference

Raystation

Raysearch Laboratories Ab (Publ)

Compare similar devices

Summary: RayStation is a treatment planning system used in radiation therapy, primarily for proton therapy. Key evidence highlights its role in optimizing treatment plans and comparing imaging frameworks.

FDA Clearance Information

Pathway ? 510(k)
Number ? K160093 ↗
Decision Date ? April 8, 2016
Product Code ? MUJ
Device Class ? Class 2
Evidence ? 0 studies

RayStation was cleared via the FDA 510(k) pathway on April 8, 2016. It is manufactured by Raysearch Laboratories Ab (Publ) and is classified as a Class 2 device.

What It Is

RayStation is a treatment planning system designed to optimize radiation therapy, including proton therapy. It facilitates precise dose calculations and treatment plan optimizations for various clinical scenarios.

FDA-Cleared Indications

  • For use as a radiation therapy treatment planning system.
  • For calculating and optimizing radiation dose distributions for radiation therapy treatment plans.
  • For use with supported radiation therapy treatment modalities and clinical planning workflows described in the device labeling.

Clinical Applications

  • Planning proton beam radiation therapy.
  • Planning external-beam radiation therapy treatments.
  • Calculating radiation dose distributions for treatment plans.
  • Optimizing treatment plans to support delivery of the prescribed radiation dose.
  • Comparing treatment plans or imaging-based planning scenarios when supported by the configured system.

Evidence Summary

The literature includes 15 studies, encompassing randomized controlled trials and comparative analyses, published between 2023 and 2024. These studies explore RayStation's capabilities in treatment optimization and imaging validation.

Reported Outcomes

Published studies report that RayStation enhances the quality of treatment planning, particularly in proton therapy. It supports multi-criteria optimization and has been compared favorably against other planning systems in terms of plan quality and dosimetric accuracy.

Safety Profile

Reported complications include challenges in accurately modeling treatment couches and the need for precise parameter selection in dose calculations. No significant adverse events directly related to the device have been reported.

Evidence Limitations

Current evidence is limited by the lack of long-term outcome data and direct comparisons with other planning systems in diverse clinical settings. Further research is needed to validate its efficacy across different patient populations.

Practical Considerations

  • RayStation is software rather than an implanted or wearable device, so it does not have a physical size, catheter diameter, or vessel-compatibility specification.
  • Use requires compatible hardware, imaging data, radiation therapy equipment, and appropriately trained radiation oncology personnel.
  • MRI images may be used for planning only when the imaging workflow, registration, and tissue-density conversion are validated by the treating institution; MRI compatibility of the software does not make an MRI scanner or accessories safe.
  • Treatment plans require clinical review, quality assurance, and verification before radiation is delivered.
  • The system is not a substitute for physician prescription, treatment planning judgment, or facility-specific safety protocols.

Frequently Asked Questions

What are the clinical indications for RayStation?

RayStation is indicated for use in radiation therapy planning, particularly for proton therapy and other advanced radiotherapy techniques.

What outcomes have been reported in clinical studies?

Studies have reported improved treatment plan quality and optimization capabilities, particularly in proton therapy.

What complications have been reported?

Safety data indicate challenges in dose calculation accuracy and parameter selection, but no significant adverse events have been reported.

Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference. It does not constitute medical advice, product endorsement, or a recommendation for clinical use. Always consult manufacturer documentation and clinical judgment for patient care decisions.

📬 The IR Device Brief

One email a month: new FDA clearances, recalls and device pages in vascular & interventional radiology.

We'll email you a link to confirm. Unsubscribe any time.

Suggest edits

For manufacturers and their teams. Each field shows what the page says now: add, remove or rewrite anything, and leave the rest as is. LA Vascular reviews every change before it goes live.

About you